umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Transparency throughout the production chain: a way to reduce pollution from the manufacturing of pharmaceuticals?
Department of Neuroscience and Physiology, the Sahlgrenska Academy at University of Göteborg, Box 434, SE-405 30 Göteborg, Sweden.
Umeå University, Faculty of Science and Technology, Department of Chemistry.
2009 (English)In: Regulatory toxicology and pharmacology, ISSN 0273-2300, E-ISSN 1096-0295, Vol. 53, no 3, 161-163 p.Article in journal (Refereed) Published
Abstract [en]

Recent findings have shown that wastewater from bulk drug production can be a source of very high environmental concentrations of drugs in certain locations. The release of active ingredients is often not specifically regulated, and thus rapid initiatives from the industries themselves are warranted. Possible ways to stimulate action include changes in local and international regulations, including the implementation of appropriate environmental standards within existing industry guidelines as well as demands from prescribers and consumers of medicines. The lack of readily available information regarding the origin of drugs and the environmental impact of the production, however, prevents consumers from making informed decisions. Here, we investigated the origin of active pharmaceutical ingredients (APIs) in 242 selected products on the Swedish market. By comparing registers from Sweden and India we found that the APIs in 71 products (31%) originated from Indian manufacturers sending their waste to a treatment plant where unprecedented amount of environmental pollution with broad spectrum antibiotics and other drugs recently has been documented. We propose that increased transparency throughout the production chain would be one of several important steps to reducing pollution from the manufacturing of drugs.

Place, publisher, year, edition, pages
2009. Vol. 53, no 3, 161-163 p.
Keyword [en]
Bulk drugs, Waste water treatment, Manufacture, Regulations, Pollution
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:umu:diva-26777DOI: 10.1016/j.yrtph.2009.01.008PubMedID: 19545507OAI: oai:DiVA.org:umu-26777DiVA: diva2:274097
Available from: 2009-10-27 Created: 2009-10-27 Last updated: 2017-12-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Fick, Jerker
By organisation
Department of Chemistry
In the same journal
Regulatory toxicology and pharmacology
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 58 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf